A Sydney law firm that brought a class action against Boston Scientific over allegedly defective pelvic mesh products has agreed to stay its case while a class action by Shine Lawyers moves ahead.
Six of the world’s largest car makers have agreed to settle class actions accusing them of selling cars with deadly Takata airbags.
Despite a judge’s urging for the parties to arrive at a “pragmatic solution”, the lawyers behind competing pelvic mesh class actions against Boston Scientific will duke it out for carriage of the proceedings.
The High Court has rejected a bid by a group of insurers to weigh in on a test case against COVID-19 related claims in business interruption policies, following a high stakes loss in the NSW Court of Appeal, which found an infectious disease exclusion did not apply.
A Johnson & Johnson unit wants the High Court to review the Full Federal Court’s rejection of its challenge to a landmark class action ruling that found the company’s pelvic mesh implants were defective and that it failed to adequately warn about their risks.
Star Entertainment Group Ltd is facing a lawsuit brought by a high-roller claiming the casino giant owes him almost $14 million won at the Baccarat table over a seven-day gambling spree last year.
Whistleblower JPMorgan can’t be a witness in a criminal cartel case over a $2.5 billion ANZ share placement that has ensnared several investment banks and top executives and claim privilege over witness statements relevant to the case, a court has heard.
The Full Federal Court has tossed an appeal by Johnson & Johnson unit Ethicon challenging a landmark decision that put it on the hook for paying damages to 10,000 women who suffered injury through defects in its prolapse mesh and incontinence tape implants.
Pelvic mesh device maker Astora Women’s Health is weighing whether to make admissions in a class action over allegedly defective products in light of a similar, high profile class action brought against Johnson & Johnson unit Ethicon over the devices.
A group representing insurers has filed another test case over pandemic coverage in business interruption policies, following a landmark loss in a test case concerning an infectious disease exclusion that could cost insurers $10 billion.